Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta Transcript

FollowPlay Earnings CallPlay Earnings Call Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Clinical Results in Primary Sclerosing Cholangitis and Hepatitis Delta May 4, 2026 8:30 AM EDT Company Participants Andrew McKibben – Senior Vice President, Strategic Finance & Investor RelationsChristopher Peetz – CEO & DirectorJoanne M.…

Finance

Economy

Markets

Fintech

Real Estate

Latest News

View More